MASI · Masimo Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $403.60M | $371.50M | $370.90M | $372.00M | - | $504.60M | $496.30M | $492.80M | - | $478.90M |
| Cost of Revenue | $152.80M | $140.90M | $137.60M | $138.00M | - | $241.40M | $241.50M | $251.10M | - | $244.10M |
| Gross Profit | $250.80M | $230.60M | $233.30M | $234.00M | - | $263.20M | $254.80M | $241.70M | - | $234.80M |
| R&D | $30.00M | $30.50M | $29.90M | $33.90M | - | $48.30M | $49.00M | $47.80M | - | $46.50M |
| SG&A | $143.40M | $116.40M | $138.90M | $119.40M | - | $184.80M | $177.50M | $159.90M | - | $156.10M |
| Total Operating Expenses | $173.40M | $147.00M | $168.80M | $156.00M | - | $233.10M | $226.50M | $207.70M | - | $209.60M |
| D&A | $8.10M | $6.20M | $6.40M | $8.60M | - | $10.30M | $10.80M | $24.30M | - | $10.70M |
| Operating Income | $77.40M | $83.60M | $64.50M | $78.00M | - | $30.10M | $28.30M | $34.00M | - | $25.20M |
| Interest Expense | $6.10M | $8.80M | $8.20M | $11.20M | - | $10.50M | $11.00M | $12.00M | - | $12.80M |
| Income Tax | $15.00M | $21.20M | $10.50M | $21.20M | - | $1.80M | $3.90M | $6.00M | - | $3.40M |
| Net Income | $57.10M | ($100.40M) | $51.30M | ($170.70M) | - | $9.80M | $16.00M | $18.90M | - | $10.60M |
| EPS - Basic | $1.10 | ($1.86) | $0.95 | ($3.17) | - | $0.18 | $0.30 | $0.36 | - | $0.20 |
| EPS - Diluted | $1.09 | ($1.84) | $0.94 | ($3.12) | - | $0.18 | $0.29 | $0.35 | - | $0.20 |
Balance Sheet
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $124.60M | $312.30M | $149.60M | $130.80M | $177.60M | $158.50M | $129.60M | $157.60M | $163.00M | $124.40M |
| Accounts Receivable | $238.70M | - | - | - | $283.20M | $371.00M | $337.70M | $330.70M | $355.50M | $356.90M |
| Inventory | $400.00M | $338.60M | $318.50M | $301.20M | $459.20M | $569.90M | $513.00M | $506.10M | $545.00M | $584.60M |
| Accounts Payable | $89.00M | $117.90M | $135.70M | $124.90M | $252.80M | $280.80M | $216.00M | $203.10M | $251.50M | $283.50M |
| Current Assets | $870.50M | $1.05B | $1.27B | $1.18B | $1.23B | $1.28B | $1.14B | $1.17B | $1.23B | $1.24B |
| Total Assets | $1.64B | $1.82B | $2.40B | $2.29B | $2.63B | $3.09B | $2.89B | $2.96B | $3.04B | $3.00B |
| Current Liabilities | $325.40M | $369.70M | $592.10M | $546.50M | $617.70M | $637.60M | $546.20M | $504.20M | $563.80M | $578.80M |
| Long-term Debt | $445.70M | $559.10M | $598.70M | $636.00M | $727.90M | $733.20M | $746.50M | $841.40M | $871.70M | $910.10M |
| Total Liabilities | $853.80M | $1.01B | $1.36B | $1.35B | $1.57B | $1.62B | $1.53B | $1.59B | $1.68B | $1.72B |
| Stockholders' Equity | $788.90M | $810.00M | $1.04B | $946.40M | $1.05B | $1.46B | $1.37B | $1.37B | $1.36B | $1.28B |
| Retained Earnings | $1.40B | $1.27B | $1.37B | $1.32B | $1.49B | $1.84B | $1.83B | $1.81B | $1.80B | $1.76B |
Cash Flow
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $45.30M | - | - | $31.10M | - | - | - | $45.80M | - | - |
| Investing Cash Flow | ($4.20M) | - | - | $10.70M | - | - | - | ($18.90M) | - | - |
| Financing Cash Flow | ($70.20M) | - | - | ($47.80M) | - | - | - | ($26.50M) | - | - |
| CapEx | $4.30M | - | - | $2.60M | - | - | - | $8.20M | - | - |
| Free Cash Flow | $41.00M | - | - | $28.50M | - | - | - | $37.60M | - | - |
Ratios
| Metric | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 62.1% | 62.1% | 62.9% | 62.9% | - | 52.2% | 51.3% | 49.0% | - | 49.0% |
| Operating margin | 19.2% | 22.5% | 17.4% | 21.0% | - | 6.0% | 5.7% | 6.9% | - | 5.3% |
| EBITDA margin | 21.2% | 24.2% | 19.1% | 23.3% | - | 8.0% | 7.9% | 11.8% | - | 7.5% |
| Net margin | 14.1% | -27.0% | 13.8% | -45.9% | - | 1.9% | 3.2% | 3.8% | - | 2.2% |
| Free cash flow margin | 10.2% | - | - | 7.7% | - | - | - | 7.6% | - | - |
| FCF / Net income | 0.72 | - | - | -0.17 | - | - | - | 1.99 | - | - |
| R&D / Revenue | 7.4% | 8.2% | 8.1% | 9.1% | - | 9.6% | 9.9% | 9.7% | - | 9.7% |
| SG&A / Revenue | 35.5% | 31.3% | 37.4% | 32.1% | - | 36.6% | 35.8% | 32.4% | - | 32.6% |
| Effective tax rate | 20.8% | - | 17.0% | - | - | 15.5% | 19.6% | 24.1% | - | 24.3% |
| Return on assets | 3.5% | -5.5% | 2.1% | -7.4% | - | 0.3% | 0.6% | 0.6% | - | 0.4% |
| Return on equity | 7.2% | -12.4% | 4.9% | -18.0% | - | 0.7% | 1.2% | 1.4% | - | 0.8% |
| Return on invested capital | 5.0% | 4.8% | 3.3% | 3.9% | - | 1.2% | 1.1% | 1.2% | - | 0.9% |
| Liquidity | ||||||||||
| Current ratio | 2.68 | 2.84 | 2.14 | 2.17 | 1.98 | 2.01 | 2.09 | 2.31 | 2.18 | 2.14 |
| Quick ratio | 1.45 | 1.92 | 1.61 | 1.62 | 1.24 | 1.11 | 1.15 | 1.31 | 1.22 | 1.13 |
| Cash ratio | 0.38 | 0.84 | 0.25 | 0.24 | 0.29 | 0.25 | 0.24 | 0.31 | 0.29 | 0.21 |
| Leverage | ||||||||||
| Debt / Equity | 0.56 | 0.69 | 0.57 | 0.67 | 0.69 | 0.50 | 0.55 | 0.62 | 0.64 | 0.71 |
| Debt / Assets | 0.27 | 0.31 | 0.25 | 0.28 | 0.28 | 0.24 | 0.26 | 0.28 | 0.29 | 0.30 |
| Debt / EBITDA | 5.21 | 6.23 | 8.44 | 7.34 | - | 18.15 | 19.09 | 14.43 | - | 25.35 |
| Interest coverage | 12.7x | 9.5x | 7.9x | 7.0x | - | 2.9x | 2.6x | 2.8x | - | 2.0x |
| Equity multiplier | 2.08 | 2.24 | 2.30 | 2.42 | 2.50 | 2.11 | 2.11 | 2.17 | 2.23 | 2.35 |
| Liabilities / Assets | 0.52 | 0.55 | 0.57 | 0.59 | 0.60 | 0.53 | 0.53 | 0.54 | 0.55 | 0.57 |
| Efficiency | ||||||||||
| Asset turnover | 0.25 | 0.20 | 0.15 | 0.16 | - | 0.16 | 0.17 | 0.17 | - | 0.16 |
| Inventory turnover | 0.38 | 0.42 | 0.43 | 0.46 | - | 0.42 | 0.47 | 0.50 | - | 0.42 |
| Days sales outstanding | 216d | - | - | - | - | 268d | 248d | 245d | - | 272d |
| Days inventory outstanding | 955d | 877d | 845d | 797d | - | 862d | 775d | 736d | - | 874d |
| Days payable outstanding | 213d | 305d | 360d | 330d | - | 425d | 326d | 295d | - | 424d |
| Cash conversion cycle | 959d | - | - | - | - | 705d | 697d | 685d | - | 722d |
| Valuation | ||||||||||
| P / E | 163.8x | - | 178.9x | - | - | 740.0x | 434.3x | 419.6x | - | 438.4x |
| P / B | 11.9x | 9.5x | 8.8x | 9.5x | - | 4.9x | 5.0x | 5.8x | - | 3.7x |
| P / S | 23.3x | 20.7x | 24.9x | 24.1x | - | 14.3x | 13.8x | 16.2x | - | 9.9x |
| EV / EBITDA | 113.6x | 88.4x | 136.3x | 109.3x | - | 193.3x | 190.7x | 148.3x | - | 153.5x |
| Growth | ||||||||||
| Revenue growth (YoY) | 8.5% | -26.4% | -25.3% | -24.5% | - | 5.4% | 9.0% | 62.0% | - | 55.8% |
| Revenue CAGR (3y) | 9.9% | 6.5% | -13.1% | 6.9% | - | 18.0% | 17.6% | 18.1% | - | 19.9% |
| Revenue CAGR (5y) | 6.2% | 6.0% | 4.3% | 6.6% | - | 17.1% | 16.7% | 16.3% | - | 17.9% |
| Gross profit growth (YoY) | 7.2% | -12.4% | -8.4% | -3.2% | - | 12.1% | 15.2% | -15.1% | - | -16.9% |
| Operating income growth (YoY) | -0.8% | 177.7% | 127.9% | 129.4% | - | 19.4% | -3.4% | -10.5% | - | -54.0% |
| Net income growth (YoY) | - | - | 220.6% | - | - | -7.5% | 1.9% | -11.3% | - | -72.0% |
| EPS growth (YoY) | - | - | 224.1% | - | - | -10.0% | 0.0% | -10.3% | - | -71.4% |
| EPS CAGR (3y) | 40.9% | - | 41.8% | - | - | -43.5% | -30.9% | -27.5% | - | -38.3% |
| EPS CAGR (5y) | 3.4% | - | -0.4% | - | - | -26.9% | -18.2% | -16.6% | - | -27.8% |
| FCF growth (YoY) | 43.9% | - | - | -24.2% | - | - | - | - | - | - |
| FCF CAGR (5y) | -4.0% | - | - | 39.7% | - | - | - | 1.2% | - | - |
| Book value growth (YoY) | -16.6% | -44.6% | -23.8% | -30.7% | -22.9% | 14.7% | 4.6% | 2.6% | 1.9% | 1.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-01-03.
Business segments
$1.52B totalHealth Care Segment$1.52B · 100.0%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing MASIMO CORP against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Nov 23, 2012 | $1.0000 |
| Dec 3, 2010 | $0.7500 |
| Mar 9, 2010 | $2.0000 |